Industry Takes Round 1 In Patent Office Rule Dispute, Gets Temporary Hold
This article was originally published in The Gray Sheet
Executive Summary
GlaxoSmithKline won a reprieve for life science industries when a federal court agreed to temporarily halt implementation of new patent rules that would have limited the number of continuation applications a patent holder can file